Biotech Values

[poorgradstudent]

GNVC:

>They promise to reveal data points with K_M curve at ASCO '09.<

One other piece of important data is probably the balance of post-TNFerade treatments between arms. Did more people on TNFerade progress and move to gemzar / tarceva as compared to the SOC?

It's just very suspicious that the clinical benefit arises 8-10 months after drug injection. Post-treatment therapy becomes a big question in such scenarios, imo.